L-leucine in Diamond Blackfan Anemia Patients

Status Recruiting

Clinical Trial Summary

Diamond-Blackfan anemia (DBA) is a rare congenital syndrome associated with physical anomalies, short stature, red cell aplasia, and an increased risk of malignancy.

Mutations affecting genes encoding ribosomal proteins cause DBA. Genetic studies have identified heterozygous mutations in at least one of eight ribosomal protein genes in up to 50% of cases.

25% of patients carry a mutation in the ribosomal protein (RP)S19 gene, whereas mutations in RPS24, RPS17, RPL35A, RPL11, and RPL5 are rare.

p53 activation has been identified as a key component in the pathophysiology of DBA after cellular and molecular studies. Other potential mechanisms that warrant further investigation include impaired translation as the result of ribosomal insufficiency, which may be ameliorated by Leucine supplementation.

Despite significant improvements in understanding of the pathophysiology of Diamond Blackfan anemia (DBA), there have been few advances in therapy. The cornerstones of treatment remain corticosteroids,chronic red blood cell transfusions, and hematopoietic stem cell transplantation, each of which is fraught with complications. Other treatments have been shown to be effective in only a few patients or in individual case reports : IL-3, cyclosporine (alone or in combination with steroids), metaclopramide. Gene therapy is still a part of research programs.

There are some indications that the Amino Acid (AA) L-leucine, a translation enhancer, may have some efficacy in DBA and 5q-syndrome, which has the same altered ribosome functions as the DBA. L-leucine is an essential AA that is unique among the branched-chain AA acting as a nutrient regulator of protein synthesis in skeletal muscle and adipose tissue.

Several preclinical studies with DBA lymphocytes exposed to various L-leucine doses, have demonstrated that protein synthesis can be increased by using high doses L-leucine.

Recent clinical data on L-leucine therapeutic use have demonstrated increase the hemoglobin level and transfusion independence in patients with DBA and 5q-syndrom.

These data support the rationale for clinical trial on L-leucine use as a therapeutic agent for DBA patients.

Clinical Trial Description

Experimental: one arm L-leucine , dose- 700mg/m2 , per os, 3 time a day, 6 months ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02386267
Study type	Interventional
Source	Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache
Contact	Natalia - SMETANINA, MD, PhD
Phone	+7 985 647 13 05
Email	Nataliya.Smetanina@fccho-moscow.ru
Status	Recruiting
Phase	Phase 2
Start date	September 2014
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02179359` - Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies	N/A
Terminated	`NCT03966053` - The Use of Trifluoperazine in Transfusion Dependent DBA	Phase 1/Phase 2
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Completed	`NCT00235391` - Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload	Phase 3
Recruiting	`NCT00027274` - Cancer in Inherited Bone Marrow Failure Syndromes
Recruiting	`NCT01758042` - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders	N/A
Terminated	`NCT00001962` - A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure	Phase 2
Completed	`NCT01362595` - Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia	Phase 1/Phase 2
Completed	`NCT03513328` - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation	Phase 1/Phase 2
Terminated	`NCT03733249` - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study	Phase 1/Phase 2
Terminated	`NCT01464164` - Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia	Phase 1/Phase 2
Completed	`NCT00011505` - Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia	Phase 2
Terminated	`NCT02065869` - Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant	Phase 1/Phase 2
Recruiting	`NCT04099966` - AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.